Award Details: Nomi Materials Corp received a $1.23M Cooperative Agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), effective October 1, 2025, through September 30, 2027.
Products and Services: The awardee will develop and commercialize scalable synthetic mucin biomaterials—engineered glycosylated polypeptides designed to replicate the structure and function of natural mucins with improved scalability, stability, purity, and customization capabilities. Phase II deliverables include: (1) at-scale synthesis processes for synthetic mucins; (2) skincare and wound healing product formulations; (3) synthetic mucins for molecular delivery applications, including mucosal barrier models; (4) anti-icing aerospace coatings utilizing synthetic mucin technology; and (5) synthetic mucin-based eye lubricant formulations. The platform leverages a common synthetic mucin polymer across multiple applications to address multi-million-dollar markets in healthcare, defense, and aerospace sectors. While subawards are planned, specific sub-awardee details were not provided in this award documentation.